Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | PARG | Q86W56 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.36 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | TYMS | P04818 | 2/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21870525 | 0.87 | MAPT (0.61) | MAPTMAPK1CYP3A4LMNAAPEX1 | |
| SCHEMBL31575668 | 0.85 | CYP1A2 (0.39) | MAPTMAPK1CYP3A4LMNAAPEX1 | |
| SCHEMBL722687 | 0.85 | MAPT (0.42) | MAPTMAPK1CYP3A4LMNAAPEX1 | |
| SCHEMBL241172 | 0.84 | CYP3A4 (0.43) | MAPTMAPK1CYP3A4LMNAAPEX1 | |
| SCHEMBL30738146 | 0.84 | CYP3A4 (0.43) | MAPTMAPK1CYP3A4LMNAAPEX1 | |
| SCHEMBL28392020 | 0.83 | PARP1 (0.43) | TYMS | |
| SCHEMBL23557300 | 0.79 | MAPT (0.61) | MAPTMAPK1CYP3A4LMNAAPEX1 | |
| SCHEMBL22462704 | 0.79 | MAPT (0.61) | MAPTMAPK1CYP3A4LMNAAPEX1 | |
| SCHEMBL1317870 | 0.79 | LMNA (0.50) | MAPTMAPK1CYP3A4LMNAAPEX1 | |
| SCHEMBL28522151 | 0.79 | TRPA1 (0.42) | MAPTCYP3A4TRPA1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112358447-B | Synthesis method of 7-fluoroisoquinoline-1-carboxylic acid | 苏州康润医药有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-11261199-B2 | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-03-01 | — | — | US | disclosed |
| US-11230558-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-01-25 | — | — | US | disclosed |
| US-11230558-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-01-25 | — | — | US | disclosed |
| US-11008341-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008341-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-05-18 | — | — | US | disclosed |
| CN-112358447-A | Synthesis method of 7-fluoroisoquinoline-1-carboxylic acid | 苏州康润医药有限公司 | 2021-02-12 | — | — | CN | disclosed |
| US-10865214-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | The Trustees of Columbia University in they City of New York (US) | 2020-12-15 | — | — | US | disclosed |
| US-10865214-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | The Trustees of Columbia University in they City of New York (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200216469-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | UNIV COLUMBIA (US) | 2020-07-09 | — | — | US | disclosed |
| EP-1629000-A2 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | Bristol-Myers Squibb Company (US) | 2006-03-01 | — | — | EP | disclosed |
| US-6995174-B2 | for inhibiting proteases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-07 | — | — | US | disclosed |
| CN-1668297-A | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2005-09-14 | — | — | CN | disclosed |
| US-20050090432-A1 | Macrocyclic isoquinoline peptide inhibitors of Hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-28 | — | — | US | disclosed |
| EP-1505963-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2004094452-A2 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004094452-A2 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040106559-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008341-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | MAPT, SQSTM1, ATG7 | MAPT 1/4885MAPK1 2068/4885CYP3A4 4230/4885 |
| US-20050090432-A1 | Macrocyclic isoquinoline peptide inhibitors of Hepatitis C virus | VIP, QPCT, HCCS | MAPT 4318/4885MAPK1 2193/4885CYP3A4 2273/4885 |
| US-11261199-B2 | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies | MAPT, SQSTM1, ATG7 | MAPT 1/4885MAPK1 2068/4885CYP3A4 4230/4885 |
| US-20040106559-A1 | Hepatitis C virus inhibitors | HAVCR2, HCCS, RNASE1 | MAPT 4314/4885MAPK1 1573/4885CYP3A4 261/4885 |
| US-11230558-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | MAPT, SQSTM1, ATG7 | MAPT 1/4885MAPK1 2068/4885CYP3A4 4230/4885 |
| US-10865214-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | MAPT, SQSTM1, ATG7 | MAPT 1/4885MAPK1 2068/4885CYP3A4 4230/4885 |
| US-20200216469-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | MAPT, SQSTM1, ATG7 | MAPT 1/4885MAPK1 2068/4885CYP3A4 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.